S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Laser breakthrough could send stock soaring 2,467% (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
66,000% upside on tiny biotech? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
Trudeau pledges Canada's support for Ukraine and punishment for Russia
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Laser breakthrough could send stock soaring 2,467% (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
66,000% upside on tiny biotech? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
Trudeau pledges Canada's support for Ukraine and punishment for Russia
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Laser breakthrough could send stock soaring 2,467% (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
66,000% upside on tiny biotech? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
Trudeau pledges Canada's support for Ukraine and punishment for Russia
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Laser breakthrough could send stock soaring 2,467% (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
66,000% upside on tiny biotech? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
Trudeau pledges Canada's support for Ukraine and punishment for Russia
NASDAQ:VIRX

Viracta Therapeutics (VIRX) Competitors

$1.15
+0.04 (+3.60%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.10
▼
$1.16
50-Day Range
$1.11
▼
$1.58
52-Week Range
$0.88
▼
$4.69
Volume
25,804 shs
Average Volume
57,818 shs
Market Capitalization
$44.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

VIRX vs. GANX, IPA, ELDN, SURF, PPBT, VINC, CMMB, PRDS, LBPH, and LTRN

Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Gain Therapeutics (GANX), ImmunoPrecise Antibodies (IPA), Eledon Pharmaceuticals (ELDN), Surface Oncology (SURF), Purple Biotech (PPBT), Vincerx Pharma (VINC), Chemomab Therapeutics (CMMB), Pardes Biosciences (PRDS), Longboard Pharmaceuticals (LBPH), and Lantern Pharma (LTRN). These companies are all part of the "medical" sector.

Viracta Therapeutics vs.

Viracta Therapeutics (NASDAQ:VIRX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.

Viracta Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.

In the previous week, Gain Therapeutics had 5 more articles in the media than Viracta Therapeutics. MarketBeat recorded 5 mentions for Gain Therapeutics and 0 mentions for Viracta Therapeutics. Gain Therapeutics' average media sentiment score of 0.69 beat Viracta Therapeutics' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Viracta Therapeutics Neutral
Gain Therapeutics Positive

Viracta Therapeutics received 4 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 67.74% of users gave Viracta Therapeutics an outperform vote while only 54.84% of users gave Gain Therapeutics an outperform vote.

CompanyUnderperformOutperform
Viracta TherapeuticsOutperform Votes
21
67.74%
Underperform Votes
10
32.26%
Gain TherapeuticsOutperform Votes
17
54.84%
Underperform Votes
14
45.16%

25.8% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Gain Therapeutics shares are held by institutional investors. 7.4% of Viracta Therapeutics shares are held by insiders. Comparatively, 11.0% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Viracta Therapeutics' return on equity of -106.11% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viracta TherapeuticsN/A -106.11% -61.96%
Gain Therapeutics N/A -130.18%-95.89%

Gain Therapeutics has higher revenue and earnings than Viracta Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viracta TherapeuticsN/AN/A-$49.20M-$1.38-0.83
Gain Therapeutics$140K302.99-$17.59M-$1.82-1.84

Viracta Therapeutics presently has a consensus target price of $9.50, suggesting a potential upside of 726.09%. Gain Therapeutics has a consensus target price of $9.20, suggesting a potential upside of 175.45%. Given Viracta Therapeutics' higher probable upside, research analysts plainly believe Viracta Therapeutics is more favorable than Gain Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viracta Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Gain Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Viracta Therapeutics beats Gain Therapeutics on 9 of the 15 factors compared between the two stocks.


Get Viracta Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VIRX vs. The Competition

Export to Excel
MetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$44.37M$5.88B$4.49B$6.27B
Dividend YieldN/A2.75%2.58%6.51%
P/E Ratio-0.834.49111.7711.93
Price / SalesN/A145.072,859.2565.45
Price / CashN/A20.7192.75100.49
Price / Book0.793.783.764.83
Net Income-$49.20M$198.29M$122.26M$186.05M
7 Day Performance-9.45%-5.73%-2.59%-3.10%
1 Month Performance-19.01%-9.27%-3.58%-5.68%
1 Year Performance-71.60%8.39%9.52%5.50%

Viracta Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GANX
Gain Therapeutics
2.1323 of 5 stars		$3.52
-0.6%		$9.20
+161.4%		+0.3%$44.70M$140,000.00-1.9328Short Interest ↓
IPA
ImmunoPrecise Antibodies
1.9905 of 5 stars		$1.91
+6.7%		$8.00
+318.8%		-56.9%$47.85M$15.61M-3.03102Analyst Revision
ELDN
Eledon Pharmaceuticals
2.0926 of 5 stars		$1.24
+8.8%		$9.00
+625.8%		-59.9%$29.20MN/A-0.2117Positive News
Gap Up
SURF
Surface Oncology
1.9414 of 5 stars		$1.07
-0.9%		$5.25
+390.7%		+1.4%$65.08M$30M-0.7035High Trading Volume
PPBT
Purple Biotech
1.8579 of 5 stars		$1.10
-1.8%		$9.33
+748.5%		-46.4%$20.33M$1M-1.0020News Coverage
Positive News
VINC
Vincerx Pharma
2.3481 of 5 stars		$0.92
+3.4%		$4.00
+335.3%		-14.8%$19.65MN/A-0.3541Gap Up
CMMB
Chemomab Therapeutics
2.2143 of 5 stars		$1.02
-1.9%		$7.00
+586.3%		-65.7%$11.27MN/A-0.3520Positive News
PRDS
Pardes Biosciences
2.0154 of 5 stars		$2.16
flat		$3.50
+62.0%		-1.8%$133.95MN/A-1.6757Positive News
LBPH
Longboard Pharmaceuticals
2.0568 of 5 stars		$5.83
-4.3%		$17.40
+198.5%		+43.8%$133.97MN/A-2.2932Positive News
LTRN
Lantern Pharma
1.8509 of 5 stars		$3.94
+0.8%		$11.00
+179.2%		-23.1%$42.83MN/A-2.9822

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:VIRX) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -